INmune Bio Q3 2023 Gaap EPS $(0.48) Misses $(0.41) Estimate, Sales $43.00K Down From $98.00K YoY
Portfolio Pulse from saritha@benzinga.com
INmune Bio (NASDAQ:INMB) reported Q3 2023 losses of $(0.48) per share, missing the analyst consensus estimate of $(0.41) by 17.07 percent. This is a 11.63 percent decrease over losses from the same period last year. The company's sales this quarter were $43.00 thousand, a 56.12 percent decrease from the same period last year.
November 01, 2023 | 8:31 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
INmune Bio's Q3 2023 earnings missed estimates, with a larger loss per share and a significant decrease in sales compared to the same period last year.
INmune Bio's earnings report shows a larger than expected loss per share and a significant decrease in sales compared to the same period last year. This could negatively impact investor sentiment and potentially lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100